Background Rituximab is a selective, B-cell depleting, biologic agent for treating refractory rheumatoid arthritis (RA). It is a chimeric monoclonal antibody targeted against CD 20 that is promoted as therapy for patients who fail to respond to other biologics. There is evidence to suggest that ritu...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!